Information Provided By: 
Fly News Breaks for September 15, 2016
SPPI
Sep 15, 2016 | 08:11 EDT
After the FDA's cancer drug advisory panel voted against Spectrum's apaziquone, RBC Capital analyst Adrian Butt continues to believe that the drug could fulfill an unmet need. Buttr says that the company should continue its third Phase 3 study of the drug, and the analyst thinks that the drug could be approved down the road if the data is positive. Butt lowered the price target on Spectrum to $10 from $11 but keeps an Outperform rating on the shares.
News For SPPI From the Last 2 Days
There are no results for your query SPPI
